A novel method for increasing MHC presentation of oncogene derived neoantigens

Invention Novelty

The invention describes a platform technology that increases MHC presentation of oncogene derived peptide neoantigens that do not normally occur in the cell. The platform has already been used to identify a method of increasing KRAS G12 D/V derived peptide presentation on MHC- I.

Value Proposition

• The invention provides a platform to screen computationally and experimentally for a cell’s ability to present cancer neoantigens. 
• The technology provides a strategy to enhance antigen presentation and bring intracellular oncogenes to the cell surface so that they are visible by T-cell surveillance. 
• The technology provides a new dimension of therapeutic intervention for cancer as it expands the repertoire of epitopes targetable by small molecules and/or immunotherapy.
• Targeting driver oncogenes is advantageous because it is cancer specific and is essential for cancer growth.

Looking for Partners

We are looking for partnerships to further develop the technology as a platform that enhances cellular presentation of various oncogenes by MHC and to develop cancer therapeutics using this approach.

Stage of Development

Proof of concept

Data Availability

Under CDA/NDA

Patent Status

Additional Patents Pending